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Ongoing progress in research on drug exposure and adverse eventsAdverse events of drugs have substantial impact on the
quality of care and on population health [1], and valid
knowledge on these topics is indispensable for appropriate
decision making in clinical practice, health policy, and re-
search planning. Accordingly, pharmacoepidemiological
studies measuring drug exposure and identifying adverse
effects are very important [2], and improving their quality
is a matter of ongoing concern. Therefore, while the related
biases and methodological challenges have often been dealt
with in this journal [3,4], innovative contributions present-
ing progress in this field are welcome.
Bijlsma et al. faced the problem that studies on prescrip-
tion drug use commonly have a cross-sectional design. They
therefore investigated the effect of integrating a longitudinal
approach into this research domain by including the birth co-
hort dimension in trend studies on drug use. Using data from
a large drug prescription database, they conclude that adding
the birth cohort dimension is valuable, as trends can be more
accurately studied and projections of future trends can be im-
proved. From a different perspective, the validity of the as-
sessment of drug exposure based on cross-sectional data
was also evaluated by Noize and co-workers. They did so
by comparing drug exposure data obtained by repeated inter-
views with data from automated databases for a wide range
of drug classes. Reported use at cross-sectional interviews as
a proxy for chronic drug exposure between interviews was
found to be valid for drugs used on a regular basis, but not
for drugs that can be used more irregularly. In view of this,
the authors make recommendations for drug-related etiolog-
ical studies. Indeed, the ultimate goal of pharmacoepidemio-
logical and pharmacovigilance studies is to accurately
identify and assess adverse drug reactions. Accordingly,
Theophile and her team updated a logistic causality assess-
ment method, earlier published in this journal [5], to predict
the probability of such events in routine pharmacovigilance.
Using drug-event pairs from a pharmacovigilance database,
they compared this method with consensual expert judg-
ment. The updated method showed better performance than
the earlier version, and according to the authors its perfor-
mance is satisfactory for routine use.
Learning by comparing different approaches was also
the objective of Twisk and Hoekstra, who studied five sta-
tistical methods to detect developmental trajectories in
a longitudinal data set. This topic is of increasing impor-
tance because of the growing popularity of prospective co-
hort studies in analyzing individual development over time.0895-4356  2012 Elsevier Inc.
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Open access under CC BY-NC-ND license.Using both manipulated and real-life data, the authors show
that, while latent class growth analysis (LCGA) and latent
class growth mixture modeling (LCGMM) perform better
than more simple methods, all methods should be applied
with great caution.
For any prospective study, not only optimal recruitment
of participants but also sample size maintenance over the
course of a study is of vital importance. In a systematic re-
view of randomized controlled trials, David et al. therefore
aimed to identify the strengths and weaknesses of economic
evaluations focusing on the cost-effectiveness of different
sample size maintenance options. Strategies such as incen-
tives without obligation, questionnaire modifications, and
personal reply paid postage, improved program cost-
effectiveness. The authors make recommendations for
future studies.
Current guidance for meta-analyses of diagnostic test ac-
curacy is advocating that such analyses should be focused
on sensitivity, specificity, or odds ratio, rather than predic-
tive values. The reason for this is the prevailing view that
predictive values are more influenced by disease preva-
lence. But as predictive values are more easily applicable
in practice, Leeflang and colleagues empirically evaluated
this current guidance by re-analyzing 23 meta-analyses of
diagnostic accuracy. They conclude that their model for
meta-analysis of predictive values fitted the data equally
well as meta-analysis of sensitivity and specificity, and
they advise that the choice of either model should be guided
by the designs of the primary studies and sources of
heterogeneity.
Researchers, who are generally interested in the perfor-
mance of the questionnaires they present to study partici-
pants as to validity and response rate, may learn a lot
from how respondents perceive their instruments. There-
fore, Bouhnik and co-workers developed the first generic
tool for assessing Respondents’ Perceptions of Health Re-
search Questionnaires (the REP-HQ Scale). They tested
this scale in a cohort of female BBCA1/2 carriers, who
were asked to complete six self-administered question-
naires, including the REP-HQ Scale. Based on their results,
they find the new scale to be valid and reliable, but recom-
mend further testing to confirm its validity for use in other
populations. Moser and his group report on the evaluation
and validation of another scale, the eight-item ‘modified
Medical Outcomes Study Social Support Survey’
(mMOS-SS) using data from study populations of female
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properties were similar to those of the original 19-item in-
strument, which supports the use of the short version in
clinical and research settings. In a third contribution on
the evaluation of rating scales, Amin et al. report on the
most widely used generic measure of health-related quality
of life in pediatrics, the PedsQL. Their purpose was to de-
termine if, in addition to what was learned from classical
test theory, a Rasch analysis could provide further insight
regarding the behavior of this measure. Based on a study
among parents of children on active cancer treatment, the
author’s report that the analysis allowed detailed item-
level evaluation and was helpful in identifying instrument
limitations that should be further explored, also in other
populations.
To assess the quality of hospital care, time-consuming
primary record reviews are often conducted. To find a more
efficient approach, van Walraven et al. developed a method
that uses observed urgent readmission rates to compare the
latent avoidable readmission rate between hospitals. The
method was applied to 25 randomly selected Ontario
acute-care hospitals. It turned out that, while urgent read-
mission rates can indeed be used to estimate the probability
that avoidable readmission rates differ significantly be-
tween hospitals, this probability is small even when signif-
icant differences in urgent readmission rates exist. So, when
comparing the quality of care of hospitals, the method
should be used very cautiously.
Quality and accessibility of care are under pressure of
increasing prevalences of chronic conditions and multimor-
bidity, and social and environmental factors. In this context,according to Shippee and colleagues, there is a growing in-
terest in studying patient complexity as a way to understand
related dilemmas and to stimulate innovations in research,
practice, and self-care. They therefore developed a pa-
tient-centered ‘cumulative complexity model,’ which they
explicate in a narrative literature review. The authors dis-
cuss the model’s implications for analytic design, clinical
epidemiology, and clinical practice. It would be interesting
to see concrete results of applying this model to achieve fu-
ture health care improvements.
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